Steven Cohen Maxcyte, Inc. Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$3.02 - $5.1 $204,756 - $345,780	-67,800 Reduced 67.13%	33,200 $103,000
Q2 2023 Aug 14, 2023	BUY	$3.69 - $5.35 $246,492 - $357,380	66,800 Added 195.32%	101,000 $463,000
Q1 2023 May 15, 2023	SELL	$4.03 - $5.89 $1.56 Million - $2.28 Million	-386,857 Reduced 91.88%	34,200 $169,000
Q4 2022 Feb 14, 2023	BUY	$4.92 - $7.4 $1.9 Million - $2.86 Million	386,157 Added 1106.47%	421,057 $2.3 Million
Q3 2022 Nov 14, 2022	BUY	$4.52 - $6.51 $157,747 - $227,199	34,900 New	34,900 $227,000

126

62M

2.4K

2.1K

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $412M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.